Existing studies have shown that dipeptidyl peptidase-4 inhibitors (DPP4is) reduce insulin requirements and hypoglycemia events compared to insulin, and therefore may be appropriate for glycemic management of select patients with mild hyperglycemia hospitalized for noncritical conditions [9, 14]. Here, INS is linked to Hypoglycemia.